WX390 plus Toripalimab for STK11-mutated cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of an experimental pill (WX390) and an immunotherapy drug (Toripalimab) for a specific type of cervical cancer that has an STK11 gene change. It aims to see if this combination can shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a rare type of cervical cancer called gastric-type endocervical adenocarcinoma, and your tumor must have a mutation in the STK11 gene.
- You should be able to take care of yourself (up and about) and have a life expectancy of at least 3 months.
- You must have at least one tumor that can be measured on a scan.
- You cannot have had cancer treatment or major surgery in the last 30 days, or certain infections like HIV, active hepatitis B or C, or lung disease.
- You must be willing to take oral medication and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called WX390 for people whose advanced solid tumors have not responded to standard treatments. The study aims to see if WX390 can help shrink or slow the growth of these tumors.
This trial tests a combination of two drugs—an oral chemotherapy (topotecan) and an immunotherapy (toripalimab)—for advanced or recurrent endometrial cancer that has not responded to first-line treatment. The goal is to see if this combination can help control the cancer.
This trial combines the immunotherapy drug toripalimab with standard chemoradiation to treat newly diagnosed advanced cervical cancer. It aims to see if adding toripalimab improves outcomes for patients whose cancer has not spread to distant organs.
This Phase 2 study tests whether combining two medicines—anlotinib and toripalimab—can work well as first treatment for advanced (stage IV) stomach cancer. It’s meant for people who have an adequate overall health status and certain blood/organ function levels.
This Phase 2 study tests whether adding toripalimab (an immune therapy) to chemotherapy before surgery improves outcomes for people with EBV-related, locally advanced stomach or stomach-junction cancer. It aims to help the cancer respond better and reduce the chance of it coming back.
This trial tests a combination of two drugs, WX390 and Toripalimab, against standard treatments for recurrent or metastatic cervical cancer that has worsened after platinum-based chemotherapy. It aims to find a more effective treatment option.
Hear when a new Gastric Type Adenocarcinoma (GAS) With STK11 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.